Check for updates

OPEN ACCESS

EDITED BY Georgios D. Panos, Nottingham University Hospitals NHS Trust, United Kingdom

REVIEWED BY

Pablo De Gracia, University of Detroit Mercy, United States Ratnakar Tripathi, University of Missouri, United States

*CORRESPONDENCE Xuejun Fang ⊠ fangxuejun@aierchina.com

RECEIVED 12 October 2023 ACCEPTED 06 February 2024 PUBLISHED 16 February 2024

CITATION

Wang Y, Zheng J, Guo Z and Fang X (2024) Efficacy and safety of small-incision corneal intrastromal lenticule implantation for hyperopia correction: a systematic review and meta-analysis. *Front. Med.* 11:1320235.

doi: 10.3389/fmed.2024.1320235

COPYRIGHT

© 2024 Wang, Zheng, Guo and Fang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Efficacy and safety of small-incision corneal intrastromal lenticule implantation for hyperopia correction: a systematic review and meta-analysis

Yue Wang¹, Jingjing Zheng¹, Zuofeng Guo¹ and Xuejun Fang^{1,2*}

¹Ophthalmology, Liaoning Aier Eye Hospital, Shenyang, China, ²AIER School of Ophthalmology, Central South University, Changsha, China

Purpose: To assess the efficacy and safety of intrastromal lenticule implantation for the treatment of hyperopia.

Methods: A systematic search of PubMed, Web of Science, Embase, Cochrane Library, China National Knowledge Internet, and Wan Fang Database identified studies on small-incision intrastromal lenticule implantation for hyperopia correction until January 2023. The Joanna Briggs Institute (JBI) critical appraisal tool was used to assess the quality of the retrospective research, and the Methodological Index for Non-randomized Studies (MINORS) was used to assess the quality of the prospective research. This study included postoperative visual outcomes, corneal morphology, and biomechanical outcomes.

Results: A total of 456 articles were identified, of which 10 were included in the meta-analysis. Ten single-arm studies involving 190 eyes were included. A meta-analysis demonstrated that corneal intrastromal lenticule implantation treatment significantly improved hyperopia. Uncorrected distance visual acuity (UDVA) significantly improved compared to the preoperative value (p=0.027), corrected distance visual acuity showed no difference compared to the preoperative value (p=0.27), and 87% eyes have no loss of one or more lines in the Snellen lines of CDVA (p<0.00001). There was a significant difference between the spherical equivalent refractive (SE) and preoperative examination (p<0.00001), 52% of eyes had \pm 0.5 diopters (D) postoperative SE (p<0.00001), and 74% eyes had \pm 1.0 D postoperative SE (p<0.00001). The central corneal thickness (CCT) increased by 72.68µm compared to that preoperatively (p<0.00001), and corneal curvature increased by 4.18D (p<0.00001). The Q-value decreased by 0.82 (p<0.00001), and higher-order aberration (HOA) decreased by 0.66 (p<0.00001).

Conclusion: Small-incision intrastromal lenticule implantation may be an effective solution for correcting hyperopia. The effect of improved vision is significant, but further exploration is needed for changes in corneal biomechanics and long-term safety.

Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier: CRD42023432343.

KEYWORDS

lenticule implantation, hyperopia, small incision lenticule extraction, refractive, meta-analysis

1 Introduction

Hyperopia not only leads to blurred vision, but also poses a risk factor for diseases such as strabismus and bilateral amblyopia (1). For patients who want to correct hyperopia through refractive surgery, transepithelial photorefractive keratectomy (T-PRK), femtosecond laser-assisted *in-situ* keratomileusis (FS-LASIK) and small incision lenticule extraction (SMILE) can be used for the correct of hyperopia. These surgical methods can effectively correct hyperopia and ametropia; however, they all increase the risk of corneal swelling, refractive regression, and corneal epithelial implantation after surgery (2–4).

SMILE produces a corneal intrastromal lenticule with a diameter of 6–7 mm and a thickness of typically 30–130 μ m while correcting myopia. Currently, there are reports of the application of corneal intrastromal lenticule in the treatment of diseases such as keratoconus (KC), corneal ulcers, corneal dilation caused by corneal refractive surgery, and corneal infection perforation (5–8). In addition, corneal intrastromal lenticule implantation has also been applied to the surgical treatment of hyperopia, and the postoperative effects are significant (9, 10). The long-term safety of corneal intrastromal lenticule implantation for hyperopia has not been confirmed, and owing to difficulties in preserving corneal intrastromal lenticule, it has not yet been widely approved for clinical use.

More recently, the number of SMILE surgeries has rapidly increased worldwide, and research on the preservation and reuse of corneal intrastromal lenticules is also becoming more mature. Corneal intrastromal lenticules can be preserved using various methods, including ultra-low temperature freezing, glycerol preservation, and commercial cryopreservation solutions (11, 12). This study conducted a systematic review of clinical studies on the treatment of hyperopia with corneal intrastromal lenticule implantation, and a meta-analysis of postoperative indicators such as UDVA, CDVA, CCT, corneal curvature, HOAs, and changes in corneal biomechanics. The aim was to explore the effectiveness and safety of corneal intrastromal lenticule implantation in the treatment of hyperopia, and to provide new treatment ideas for corneal refractive surgery for clinical hyperopia refractive errors.

2 Methods

We performed a systematic review and meta-analysis in accordance with the Reporting Items for Systematic Reviews and Meta-Analyses Statement (13). This study was registered in the International Prospective Register of Systematic Reviews (PROSPERO; ID: CRD42023398935). The study adhered to the tenets of the Declaration of Helsinki.

2.1 Search strategy

Two researchers (YW and JZ) independently performed database searches of PubMed, EMBASE, Web of Science, the Cochrane Library, China National Knowledge Internet, and the Wanfang Database to identify relevant studies on small-incision corneal intrastromal lenticule implantation for hyperopia correction up to 2023.01.01. The search terms included "small-incision intrastromal lenticule," "lenticule implantation," and "hyperopia." The search strategy was determined after multiple pre-searches, combined with subject headings and free words.

2.2 Inclusion and exclusion criteria

The inclusion criteria were as follows: (1) the research subjects are hyperopia patients who have undergone small-incision corneal intrastromal lenticule implantation surgery. (2) For single-arm studies, the treatment modality in the included studies was corneal intrastromal lenticule implantation. For case-control studies, the experimental group comprised eyes treated with corneal intrastromal lenticule implantation, and there were no limitations on the control group intervention measures. (3) Studies that reported at least one major outcome (UDVA, CDVA, SE, and CCT) or secondary outcome (corneal biomechanical indicators and HOAs). (4) The patients included in the study had no other eye diseases. (5) Complete at least three months of follow-up.

The exclusion criteria were as follows: (1) the included patients are not those who have undergone small incision matrix lens transplantation surgery. (2) Lack of standard deviation in the research results. (3) No outcome was related to the purpose of the study. (4) Data with significant errors in research results. (5) Studies with fewer than five eyes were included. (6)Research involving duplicate patients.

The study was independently reviewed by two researchers (YW, JZ) to determine whether the included studies met the inclusion or exclusion criteria. When there was any disagreement, a third researcher (ZG) participated.

2.3 Data extraction

For all included studies, the basic characteristics of the article and the main clinical data were extracted. The basic characteristics of the article included: the lead author, year of publication, language of publication, sample size of patients and eyes, age, surgical method, and postoperative outcomes.

The primary outcome measures were visual outcome, refractive outcome, and corneal morphology change. The visual outcome included the mean logMAR value of uncorrected distance visual acuity (UDVA), mean logMAR value of corrected distance visual acuity (CDVA), and the eyes changes in the Snellen chart of CDVA. The refractive outcome included the mean postoperative spherical equivalent (SE), the percentage of eyes within ± 0.5 diopters (D) of the target refraction and the percentage of eyes within ± 1.0 D. The corneal morphology change outcome included the mean increment of corneal curvature and changes in central corneal thickness (CCT).

Secondary outcomes included postoperative high-order aberrations (HOAs), changes in *Q* values, and corneal biomechanical indicators. Among them, corneal biomechanical indicators include Corneal compensated intraocular pressure (IOPcc), Goldmann correlated intraocular pressure (IOPg), corneal hysteresis (CH), and corneal resistance factor (CRF).

Data were extracted independently by two authors (YW and JZ), and any differences were resolved through discussion until consensus was reached or a third author (ZG) is consulted.

2.4 Assessment of risk of bias

The Joanna Briggs Institute (JBI) critical appraisal tool was used to evaluate the methodological quality of retrospective studies (14, 15), and the Methodological Index for Non-randomized Studies (MINORS) was used to evaluate the methodological quality of prospective studies (16, 17). Studies were not included in our analysis if they scored lower than 6 out of 8 (75%) in retrospective studies, the scores of prospective studies must be greater than 10, and two reviewers (YW and JZ) independently evaluated the quality of the include studies. If there was a disagreement, another reviewer (ZG) participated in the discussion to obtain the results. Funnel plot and Egger's test were used to evaluate the risk of publication bias, with p < 0.05 indicating a statistically significant bias.

2.5 Statistical analysis

Statistical analysis was conducted using Stata V.16.0 software (StataCorp, College Station), and forest maps were created using RevMan software (version 5.4.1; Cochrane Collaboration). In this meta-analysis, continuous variables were extracted as mean and standard deviation (mean±SD), and estimated using the weighted

mean difference (WMD), and 95% confidential intervals (CI). Random-effects models were used when study heterogeneity was high ($l^2 > 50\%$), and fixed-effects models were used when heterogeneity was low ($l^2 \le 50\%$) (18, 19).

3 Results

3.1 Study selection

We identified 465 related articles through a preliminary search, of which 171 duplicate articles were excluded using EndNote X9 software (Clarivate Analytics, US), and 294 articles underwent title and abstract reviews. After selecting titles and abstracts, 272 studies were excluded for the following reasons: irrelevant topics (n=75), inconsistent research contents (n=64), reviews (n=53), case reports (n=18), *in vitro* experimental studies (n=17), animal studies (n=39), literature corrections (n=2), letters (n=2), and conference literature (n=1). A total of 22 articles were reviewed, of which 12 were excluded for the following reasons: no major outcome (n=3), missing data (n=3), and duplicate data (n=6). The remaining 10 reports met the qualification criteria and were included in the meta-analysis (9, 10, 20-27). The literature screening process is illustrated in Figure 1.



3.2 Study characteristics

A total of 130 (190 eyes) cases were included in the study, with an average age of 24.98 (95% CI: [22.51, 27.44]). The characteristics of the included studies are summarized in Table 1.

3.3 Quality assessment

Six of ten prospective single-arm uncontrolled studies (9, 21–23, 25, 26) were evaluated using the MINORs, with a score of 11–13 (Table 2A). The remaining four retrospective uncontrolled studies (10, 20, 24, 27) were evaluated using the JBI case series key assessment checklist and met 9 or more of the 10 criteria (Table 2B). The quality of the included studies met these criteria.

3.4 Outcomes

3.4.1 Visual outcomes

A total of six studies (9, 20, 22, 24–26) reported the of logMAR values of postoperative UDVA. At the last follow-up, postoperative UDVA increased by 0.40 logMAR compared to preoperative UDVA

TABLE 1 The basic clinical characteristics of included studies.

(WMD = -0.40, 95% CI: [-0.61, -0.19], I^2 = 88%, p = 0.0002, Figure 2A). A total six studies (9, 21–23, 25, 26) reported the logMAR values of postoperative CDVA. At the last follow-up, postoperative CDVA increased by 0.02 logMAR compared to preoperative CDVA (WMD = -0.02, 95% CI: [-0.05, -0.01], I^2 = 0%; p = 0.27, Figure 2B). All studies reported changes in the Snellen of CDVA. 87% of eyes had no loss of one or more lines in the Snellen lines of the CDVA after surgery (95% CI: [0.73, 1.01], I^2 = 0%, p < 0.0001, Figure 2C). Sensitivity analysis showed that, regardless of which article was excluded, the changes in UDVA and CDVA were stable, with no changes in heterogeneity or results.

3.4.2 Refraction outcome

All 10 studies reported the results of postoperative SE, which decreased by 5.73D compared to preoperative SE, (WMD=-5.73, 95% CI: [-6.04, -5.42], l^2 =82%, p<0.00001, Figure 3A). A total of 5 studies (21–24, 26) reported the results of the proportion of postoperative and expected refractive error within the range of ±0.5D, and the proportion of postoperative and expected refractive error within the range of ±0.5D was 51% (95% CI: [0.27, 0.74], l^2 =0%, p<0.0001, Figure 3B). A total of four studies (20, 22, 24, 26) indicated that 74% of the eyes had an error range of ±1.0D compared to the expected SE. (95% CI: [0.54, 0.94], l^2 =0%, p<0.0001, Figure 3C).

Study	Language	Design	Eyes	Surgical	Lenticule Implantation	Age	Outcomes
		single-arm study			Autologous/ Allogeneic	Mean <u>+</u> SD	
Jing Zhang (10)	English	Retrospective	24	SMILE	Allogeneic	26.40±5.82	UDVA, CDVA, SE, HOAs, CCT, IOPg, IOPcc, CH, CRF, Km, Q value
Jie Hou (20)	English	Retrospective	31	SMILE	Allogeneic	20.00 ± 1.48	UDVA, SE, CD, CCT, Km
Meng Li (23)	English	Prospective	10	LASIK	Autologous	24.70 ± 5.82	CDVA, SE
Jiawei Wu (21)	English	Prospective	10	LASIK/PTK	Allogeneic	22.80±3.29	CDVA, SE, Q value, HOAs
Ling Sun (24)	English	Prospective	5	LASIK	Autologous	24.60±5.30	UDVA, CDVA, SE, Km, CCT
Shengtao Liu (26)	English	Prospective	5	SMILE	Allogeneic	21.00 ± 2.60	UDVA, CDVA, SE, Q value, CCT, Km
Shengtao Liu (25)	English	Prospective	14	SMILE	Allogeneic	29.00 ± 9.17	UDVA, CDVA, SE, CCT, Km
Sheetal Brar (22)	English	Retrospective	42	SMILE	Allogeneic	27.04±5.33	UDVA, CDVA, SE, CCT, Km, Q value, HOAs
Mengfei Hu (27)	Chinese	Retrospective	12	SMILE	Autologous	29.25±5.02	SE, CCT, Km
Yuehua Zhou (9)	Chinese	Prospective	37	SMILE	Allogeneic	28.00±9.00	SE, Km, IOPg, IOPcc, CH, CRF,CCT

SMILE, small incision lenticule extraction; LASIK, laser *in situ* keratomileusis; UDVA, uncorrected distance visual acuity; SE, spherical equivalent; CCT, central corneal thickness; Km, K value; CD, corneal densitometry; IOPg, Goldmann correlated intraocular pressure; IOPcc, corneal compensated intraocular pressure; CH, corneal hysteresis; CFR, corneal resistance factor.

		(A) N	AINORS in	dex for inc	luded nor	n-randomiz	ed studies		
Study		Ш	Ш	IV	V	VI	VII	VIII	Total
Meng Li (23)	2	2	2	2	1	2	2	0	13
Jiawei Wu (21)	2	2	2	2	1	2	2	0	13
Ling Sun (24)	2	2	2	2	1	2	2	0	13
Shengtao Liu (26)	2	2	2	2	0	2	2	0	12
Shengtao Liu (25)	2	2	2	2	0	2	2	0	12
Yuehua Zhou (9)	2	2	2	2	1	2	2	0	13

TABLE 2 Quality assessment of included studies.

	(B) JBI cı	ritical ap	praisal cl	necklist f	or case s	eries for	included	d retrosp	ective stı	udies	
Study	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Q10	Overall appraisal
Jing Zhang (10)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Include
Jie Hou (20)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Include
Sheetal Brar (22)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Include
Mengfei Hu (27)	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	Include

Sensitivity analysis shows that regardless of which article is excluded, the changes in the above results are stable, with no heterogeneity or changes in the results.

3.4.3 CCT and corneal curvature

A total of eight studies (9, 10, 20, 22, 24–27) reported the results of CCT, with an average increase of 72.68 µm in postoperative CCT compared to preoperative CCT (WMD=72.68, 95% CI: [55.00, 90.36], I^2 =82%; p <0.00001, Figure 4A). Seven studies (9, 10, 20, 22, 24, 25, 27) reported the results of corneal curvature, with an average increase of 4.18D in postoperative corneal curvature compared to preoperative (WMD=4.18, 95% CI: [3.65, 4.71], I^2 =8%; p <0.00001,Figure 4B). Sensitivity analysis showed that regardless of which article was excluded, the changes in CCT and corneal curvature were stable, with no changes in heterogeneity or results.

3.4.4 HOAs and Q-value

Three studies (21, 22, 26) reported the results of *Q*-values, with a difference of -0.82 between postoperative and preoperative *Q*-values, indicating a relative tendency towards swelling (WMD = -0.82; 95% CI: [-1.10, -0.53], $I^2 = 90\%$, p < 0.00001, Figure 5A). Two studies (21, 22) reported the results of HOAs, with a difference of -0.55 between postoperative and preoperative HOAs (WMD = -0.55, 95% CI: - [0.66, -0.45], $I^2 = 0\%$, p < 0.00001, Figure 5B). Sensitivity analysis showed that regardless of which article was excluded, the changes in *Q*-values and HOAs were stable, with no changes in heterogeneity or results.

3.4.5 Corneal biomechanics

Two studies (9, 10) reported the results of corneal biomechanical indicators, including IOPg, IOPcc, CH, and CRF. IOPg decreased by 2.25 mmHg compared to that before surgery (WMD = -2.25; 95% CI: [-3.50, -1.01]; $l^2 = 0\%$; p = 0.0004, Figure 6A). There was no significant difference in IOPcc compared to preoperative values (WMD = -0.88, 95% CI: [-1.92, 0.15], $l^2 = 0\%$; p = 0.10, Figure 6B). CH increased by 1.02 compared to the preoperative value (WMD = 1.02, 95% CI: [0.29,

1.96], l^2 =40%, p=0.006, Figure 6C). There was no significant difference in postoperative CFR compared to preoperative values (WMD=0.02, 95% CI: [-1.03, 1.06], l^2 =57%, p=0.97, Figure 6D). Sensitivity analysis shows that regardless of which article is excluded, heterogeneity and results will change.

3.4.6 Sensitivity analysis and publication bias

Publication bias was evaluated intuitively using a funnel plot of postoperative changes in UDVA (Figure 7A), CDVA (Figure 7B), SE (Figure 7C), and CCT (Figure 7D). We also conducted Egger regression to quantitatively evaluate publication bias, and found that p (UDVA) = 0.54, p (CDVA) = 0.81, p (SE) = 0.49, and p (CCT) = 0.31, indicating that the funnel plot was symmetric, and there was no publication bias in this study.

4 Discussion

This study included 10 studies with a total of 130 patients (190 eyes). The meta-analysis results showed that the postoperative UDVA of corneal intrastromal lenticule implantation for hyperopia was significantly increased. The proportion of postoperative CDVA that reached or surpassed the preoperative CDVA was 87%. The proportion of postoperative SE error within $\pm 0.5D$ was 52%, and the proportion of postoperative SE error within $\pm 0.1.0D$ was 74%. The above results suggest that the application of corneal intrastromal lenticule implantation to correct hyperopia can effectively improve the refractive state of patients and achieve correction of refractive errors. Although LASIK surgery can also achieve the effect of correct hyperopia, significant refractive regression was observed in long-term follow-up studies (28, 29). Studies by Zhang (10), Li (23), and Sheetal (22) were followed up for 1 year, 2 years, and 3 years (1–7 years) after surgery, all showing good refractive stability.

The difference in postoperative *Q*-value compared to the preoperative *Q*-value was -0.82, which is directly related to the implantation of corneal intrastromal lenticule, leading to a relative

	Post	operat	ive	Preo	perativ	/e		Mean Difference		Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl		IV, Random, 95% Cl
Jie Hou 2022	0.36	0.26	31	0.67	0.39	31	17.7%	-0.31 [-0.47, -0.15]		
Jing Zhang 2021	0.09	0.09	24	0.37	0.23	24	19.0%	-0.28 [-0.38, -0.18]		+
Ling Sun 2016	-0.04	0.05	5	0.5	0.35	5	13.9%	-0.54 [-0.85, -0.23]		_ —
Sheetal Brar 2022	0.25	0.22	42	1.03	0.39	42	18.3%	-0.78 [-0.92, -0.64]		-
Shengtao Liu 2021	0.46	0.34	14	0.56	0.35	14	15.4%	-0.10 [-0.36, 0.16]		
Shengtao Liu 2022	0.3	0.07	5	0.66	0.27	5	15.7%	-0.36 [-0.60, -0.12]		
Total (95% CI)			121			121	100.0%	-0.40 [-0.61, -0.19]		•
Heterogeneity: Tau ²	= 0.06; C	hi² = 4	3.21, df	'= 5 (P <	< 0.000	01); I²:	= 88%			
Test for overall effect	t: Z = 3.70) (P = ().0002)						-2	Favours [Post-op] Favours [Pre-op]
3	Dect	marat		Drog	noroti			Maan Difforance		Maan Difference
Churche or Carbonness	Post	pherat	Toto	Prec	peratr	Ve Toto'	Mainta			
Study of Subgroup	mean	SD	Total	mean	SD	Total	vveight	IV, Fixed, 95% CI		IV, FIXEG, 95% CI
Jiawei Wu 2020	0.17	0.21	10	0.29	0.28	10	2.3%	5 -0.12 [-0.34, 0.10]		
Jing Zhang 2021	0.08	0.07	24	0.09	0.07	24	70.2%	5 -0.01 [-0.05, 0.03]		•
Meng Li 2017	0.14	0.13	10	0.19	0.13	10	8.5%	-0.05 [-0.16, 0.06]		
Sheetal Brar 2022	0.19	0.21	42	0.22	0.23	42	12.4%	-0.03 [-0.12, 0.06]		
Shenqtao Liu 2021	0.36	0.27	14	0.34	0.28	14	2.7%	0.02 (-0.18, 0.22)		
Shengtao Liu 2022	0.16	0.13	5	0.2	0.14	5	3.9%	-0.04 [-0.21, 0.13]		
Total (95% CI)			105			105	100.0%	.0.02[.0.05.0.01]		•
Heterogeneity: Chi ² -	1.57 df	- 6 (P	- 0 00\	· 12 – 0.00			100107		⊢	
Test for sucrell offest:	7 - 4.44	- 3 (F -	- 0.30)	1 - 0%	0				-1	-0.5 0 0.5 1
restior overall ellect.	2=1.11	(P = 0	.27)							Favours (Post-op) Favours (Pre-op)
2							Ris	sk Difference		Risk Difference
Study or Subgro	up F	lisk D	ifferei	ice	SE	We	ight IV	, Fixed, 95% Cl		IV, Fixed, 95% Cl
Jiawei Wu 2020			~ ~	0.6 0	.3086	5	.4% 0.	60 [-0.00, 1.20]		
Jie Hou 2022			0.9	U32 U 501	0.202	15	U 6%U.	0.90 [0.55, 1.25]		
Ling Sun 2016			0.93	1 0	4264	2	.0% 0 8% 1	0.90 [0.30, 1.33]		
Mengfei Hu 2021	I		0.6	 667 0	.2828	6	.4% 0	.67 [0.11, 1.22]		
Meng Li 2017				1 0	.3086	5	.4% 1	.00 [0.40, 1.60]		
Sheetal Brar 202	22		0.8	091 0	.1534	21	.8% 0	.81 [0.51, 1.11]		-
Shengtao Liu 20	21			1 0	.2626	7	.4% 1	.00 [0.49, 1.51]		
Shengtao Liu 20	22			1 0	.4264	2	.8% 1	.00 [0.16, 1.84]		
Yuenua Zhou 20	15		0.8	919 U	.1633	19	.3% 0	1.89 [0.57, 1.21]		
Total (95% CI)						100	.0% 0.	.87 [0.73, 1.01]		
Heterogeneity: C	hi⁼ = 2.	29, df	= 9 (P	= 0.99	l); l² =	0%			1	-ດໍຣ ດໍ ດໍຣ
Toot for every!	Hant. 7	- 1 - 1	0 / 0	0 000	043					0.0 0.0

(A) Forest plot showing the weighted mean difference of postoperative UDVA (logMAR) and preoperative UDVA (logMAR). (B) Forest plot showing the weighted mean difference of postoperative CDVA (logMAR) and preoperative CDVA (logMAR). (C) Forest plot showing the risk difference of postoperative CDVA (Snellen).

tendency of the cornea to bulge. After surgery, HOAs decreased by 0.55 compared to before surgery. In theory, the smaller the eccentricity of the optical region center, the lower the introduction of higher-order aberrations (30). SMILE surgery is superior to LASIK in this regard (31, 32). Different types of corneal refractive surgery can cause changes in the *Q*-value (33). Currently, *Q*-value guided LASIK surgery can be performed, and a large amount of clinical data has achieved good results (34, 35). However, this issue needs to be addressed further in the treatment of hyperopia with corneal intrastromal lenticule implantation.

The average increase in postoperative CCT compared to preoperative was 72.68 µm. After surgery, the corneal curvature increased by an average of 4.18D compared to before surgery. Corneal intrastromal lenticule implantation increases corneal thickness and effectively preserves corneal stromal thickness, avoiding the risk of corneal dilation (36). Postoperative corneal topography shows that the central part of the cornea has become significantly convex, with increased curvature, which changes the refractive power of the central part of the cornea and corrects hyperopia. At the same time, this new surgical method for correcting hyperopia avoids the possibility of passive formation of excessively high central curvature of the cornea and does not lead to surgically induced KC. In addition, changing corneal morphology through implantation is a reversible surgical approach when there are other diseases that require feasible lenticule removal surgery. In our meta-analysis, the results of the two included studies were inconsistent, and convincing and consistent evidence regarding corneal biomechanical indicators has not yet been found, which deserves further validation through case-control studies.

The corneal stroma accounts for 90% of the corneal thickness, which is crucial for ensuring the corneal transparency and refractive function necessary for normal vision. Currently, scientific research on corneal stroma mainly includes acellular or decellularized and decellularized human or animal corneas and non-corneal tissues, acellular bioengineered stromal scaffolds, tissue adhesives, 3D

4													
	Posto	perativ	/e	Preo	perativ	<i>r</i> e		Mean Differen	се		Mean Differ	ence	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95	% CI		IV, Fixed, 9	5% CI	
Jiawei Wu 2020	0.33	0.11	10	6.95	1.82	10	7.4%	-6.62 [-7.75, -5	5.49]				
Jie Hou 2022	0.52	0.82	31	5.95	2.1	31	14.9%	-5.43 [-6.22, -4	4.64]				
Jing Zhang 2021	-0.75	0.79	24	7.42	3.12	24	5.7%	-8.17 [-9.46, -6	6.88] -				
Ling Sun 2016	-1	0.91	5	4.35	1.92	5	2.7%	-5.35 [-7.21, -3	3.49]		-		
Mengfei Hu 2021	-0.6	0.01	12	3.96	1.25	12	18.8%	-4.56 [-5.27, -3	3.85]				
Meng LI 2017 Reacted Braz 2022	-0.53	1.45	10	4.40	1.97	10	4.1%	-4.99[-0.51,-3	3.47]	_			
Shenatao Liu 2022	-0.60	1.10	42	5.54	1.90	42	0.7%	-4.04 [-5.53, -4	+.10j 5.151				
Shengtao Liu 2022	-0.35	0.27	5	6.23	1.34	5	6.6%	-6.58 [-7.785	5.381				
Yuehua Zhou 2015	-0.63	0.94	37	6.84	2.79	37	10.5%	-7.47 [-8.42, -6	6.52]				
Total (95% CI)			190			190	100.0%	-5.73 [-6.04, -5	5.42]	•			
Heterogeneity: Chi ² =	50.19, di	f= 9 (P	< 0.00	001); I ^z	= 82%				-1	0 -5			10
Test for overall effect:	Z = 36.6	1 (P < 0	0.00001	I)					- 1	Favours	[Post-op] Fa	vours (Pre-op	1 10
3			_				Risk	Difference			Risk Differe	ence	
Study or Subgrou	p Ri	sk Difi	ferend	ce	SE	Weig	aht IV,	Fixed, 95% CI			<u>IV, Fixed, 95</u>	% CI	
Jiawei Wu 2020			0	.9 0.3	3086	15.3	2% 0.9	80 (0.30, 1.50)					
Ling Sun 2016			0	.2 0.	4264	8.0	0% 0.2	0 [-0.64, 1.04]				•	\longrightarrow
Meng Li 2017			0	.3 0.3	3086	15.3	2% 0.3	0 [-0.30, 0.90]				•	
Sheetal Brar 2022			0	.5 0.1	1534	61.0	6% 0.5	50 [0.20, 0.80]					
Shengtao Liu 202	1		0.571	14 0.	2626		1	lot estimable					
Total (95% CI)						100.	0% 0.5	1 [0.27. 0.74]					
Heterogeneity: Ch	i ² = 2.5	9. df =	3 (P =	: 0.46)	$ ^{2} = 0$	%			—			I	
Test for overall eff	ect: Z =	4.21 (Ρ<Ο.	0001)		~			-1	-0.5	0	0.5	1
				,									
;							Risk Diff	erence		Ri	sk Differenc	е	
Study or Subgrou) Ris	k Diffe	rence	9	E We	eight	IV, Fixed	I, 95% CI		IV.	, Fixed, 95% (1	
Jie Hou 2022		0).7742	0.178	31 33	3.5%	0.77 [0.	43, 1.12]					-
Ling Sun 2016			0.8	0.428	64 (5.8%	0.80 [-0.	04, 1.64]			+		→
Sheetal Brar 2022		0).7143	0.153	34 49	5.2%	0.71 [0.	41, 1.01]					• •
Shengtao Liu 202 [.]	I	().7143	0.262	26 19	5.4%	0.71 [0.	20, 1.23]			-		• •
Total (95% CI)					10	0.0%	0.74 [0.	54, 0.94]					
Heterogeneity: Chi	² = ∩ ∩Q	df= 3	(P = 0	99\· IZ	= 0%								
Test for overall effe	ect: Z = 7	7.17 (P	< 0.00	001)	- 0 /0			-1		-0.5	0	0.5	1
RE 3		,											

(A) Forest plot showing the weighted mean difference of postoperative SE and preoperative SE. (B) Forest plot showing the risk difference of postoperative and expected refractive error within the range of $\pm 0.5D$. (C) Forest plot showing the risk difference of postoperative and expected refractive error within the range of $\pm 1.D$.

bioprinting, and stromal stem cell therapy (37, 38). As of 2022, the global surgical volume of SMILE has exceeded 6 million cases, generating a large number of corneal stromal lenses annually. Currently, attempts have been made to apply corneal intrastromal lenticule for the treatment of diseases such as hyperopia correction, ulcerative keratitis, KC, and corneal dilation after LASIK; however, they have not yet achieved widespread clinical application. When using corneal intrastromal lenticule implantation to treat hyperopia, the corneal stroma tissue implanted in the capsule has an ordered arrangement of collagen fibers, with a lens diameter of 6.5 mm, without blood vessels or lymphatic tissue. The corneal stroma capsule is in a sterile environment, and the donor corneal stroma is not in contact with aqueous humor or tears. Therefore, the probability of corneal graft rejection and corneal infection is very low. However, in Brar's study (22), four eyes experienced immune rejection, all of which

were cryopreserved. The use of fresh corneal intrastromal lenticules can also improve graft survival and reduce the rejection rate (39). At present, research has achieved non-traditional cryopreservation of corneal stromal lenses, improving their activity and meeting the needs of corneal intrastromal lenticule implantation (40-42).

4.1 Study limitations

Through literature review and meta-analysis, we found that there are few studies on the treatment of hyperopia with corneal intrastromal lenticule implantation, and the research design has certain limitations. The number of included research cases was small, and due to the limited number of cases, it was not possible to perform subgroup analysis of corneal intrastromal lenticule implantation surgery and

	Poste	operativ	re	Preo	perative)		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Jie Hou 2022	607.14	32.28	31	538.52	30.84	31	15.3%	68.62 [52.90, 84.34]	-
Jing Zhang 2021	556.59	36.91	24	529.25	41.25	24	13.7%	27.34 [5.19, 49.49]	
Ling Sun 2016	616.2	36.27	5	560	35.86	5	8.2%	56.20 [11.49, 100.91]	 →
Mengfei Hu 2021	629.17	41.41	12	538.33	22.12	12	12.5%	90.84 [64.28, 117.40]	
Sheetal Brar 2022	625.76	41.69	42	550.02	29.68	42	15.4%	75.74 [60.26, 91.22]	+
Shenatao Liu 2021	675.8	25.87	14	572.3	12.98	14	15.4%	103.50 [88.34, 118.66]	-
Shenatao Liu 2022	689	71.91	5	563.2	49.56	5	4.1%	125.80 [49.25, 202.35]	
Yuehua Zhou 2015	612	37	37	549	30	37	15.4%	63.00 [47.65, 78.35]	-
			470			470	400.0%	70 00 155 00 00 001	
Total (95% CI)			170			170	100.0%	(2.68155.00.90.361	
Total (95% CI)	167 24-0		1/U 7 00 df	-7/0~	0 00004	170 \\B=0	100.0%	72.68 [55.00, 90.36]	\ \
Total (95% Cl) Heterogeneity: Tau² =	467.21;0	Chi ² = 3	170 7.98, df	= 7 (P <	0.00001	170); l² = 8	100.0% 2%	72.68 [55.00, 90.36]	-200 -100 0 100 200
Total (95% CI) Heterogeneity: Tau² = Test for overall effect: 2	467.21; (Z = 8.06 (Chi² = 3 (P < 0.0)	170 7.98, df 2001)	=7(P≺	0.00001	170); I² = 8	2%	72.68 [55.00, 90.36]	
Total (95% Cl) Heterogeneity: Tau ² = Test for overall effect: 2	467.21; (Z = 8.06 (Chi² = 3' (P < 0.0)	170 7.98, df 0001)	°=7(P≺	0.00001	170); I ² = 8	2%	72.68 [55.00, 90.36]	-200 -100 0 100 200 Favours [Post-op] Favours [Pre-op]
Total (95% Cl) Heterogeneity: Tau² = Test for overall effect: J	467.21; (Z = 8.06 (Chi² = 3 (P < 0.0)	170 7.98, df 2001)	=7(P≺	0.00001	170); ²= 8	2%	72.68 [55.00, 90.36]	-200 -100 0 100 200 Favours (Post-op) Favours (Pre-op)
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 3	467.21; (Z = 8.06 (P o	Chi² = 3 (P < 0.0) stoper	170 7.98, df 2001)	= 7 (P <	0.00001	170); ² = 8	2%	72.08 [55.00, 90.36]	-200 -100 0 100 200 Favours (Post-op) Favours (Pre-op)
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 3 Study or Subgroup	467.21; (Z = 8.06 (Po Mea	Chi ² = 3 (P < 0.0) stoper	170 7.98,df 0001) ative D Tot	°=7(P≺ Pro al Mea	0.00001 eoperat	170); ² = 8 ive Total	100.0% 2%	Mean Difference	-200 -100 0 100 200 Favours [Post-op] Favours [Pre-op] Mean Difference
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 <u>Study or Subgroup</u> Jie Hou 2022	467.21; (Z = 8.06 (Po <u>Mea</u> 46.7	Chi ² = 3 (P < 0.0) stoper <u>in Si</u> 25 2.6	170 7.98,df 0001) attive <u>D Tot</u> 1 3	= 7 (P < Pro al <u>Mea</u> 31 42.9	0.00001 eoperat <u>n SD</u> 4 1.44	170); ² = 8 ive <u>Total</u> 31	100.0% 2% <u>I Weigh</u> 25.59	Mean Difference t IV, Fixed, 95% CI 3.81 [2.76, 4.86]	-200 -100 0 100 200 Favours [Post-op] Favours [Pre-op] Mean Difference IV, Fixed, 95% Cl
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 <u>Study or Subgroup</u> Jie Hou 2022 Jing Zhang 2021	467.21; (Z = 8.06 (Po <u>Mea</u> 46.7 49.1	Chi ² = 3 (P < 0.0) stoper in Si (5 2.6 9 3.8	170 7.98, df 0001) attive <u>D Tot</u> 1 3 7 2	= 7 (P < Pro al Mea 1 42.9 24 43.1	0.00001 eoperat n SD 4 1.44 9 4.37	170); ² = 8 ive <u>Total</u> 31 24	100.0% 2% <u>I Weigh</u> 25.59 5.19	Mean Difference t IV, Fixed, 95% CI % 6.00 [3.66, 8.34]	-200 -100 0 100 200 Favours [Post-op] Favours [Pre-op] Mean Difference IV, Fixed, 95% Cl
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 <u>Study or Subgroup</u> Jie Hou 2022 Jing Zhang 2021 Ling Sun 2016	467.21; (Z = 8.06 (<u>Po</u> <u>Mea</u> 46.7 49.1 46.0	Chi ² = 3 (P < 0.0) stoper (n Si (5 2.6 9 3.8)4 2.3	170 7.98, df 0001) ative <u>D Tot</u> 1 3 7 2 8	= 7 (P < <u>al Mea</u> 1 42.9 4 43.1 5 40.9	0.00001 eoperation n <u>SD</u> 4 1.44 9 4.37 8 0.99	170); ² = 8 ive <u>Total</u> 31 24 5	100.0% 2% 1 Weigh 1 25.59 4 5.19 5 5.59	Mean Difference t V, Fixed, 95% Cl % 3.81 (2.76, 4.86) % 6.00 (3.66, 8.34) % 5.06 (2.80, 7.32)	-200 -100 0 100 200 Favours [Post-op] Favours [Pre-op] Mean Difference IV, Fixed, 95% CI
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 S <u>Study or Subgroup</u> Jie Hou 2022 Jing Zhang 2021 Ling Sun 2016 Mengfei Hu 2021	467.21; (Z = 8.06 (<u>Mea</u> 46.7 49.1 46.0 47.8	Chi ² = 3 (P < 0.0) stoper in <u>Si</u> 25 2.6 9 3.8 9 3.8 04 2.3 06 3.2	170 7.98, df 0001) attive <u>D Tot</u> 1 3 7 2 8 5 1	= 7 (P < Pro al Mean 1 42.9 2 43.1 5 40.9 2 42.	0.00001 eoperat n <u>SD</u> 4 1.44 9 4.37 8 0.99 9 1.92	170); I ² = 8 ive <u>Total</u> 31 24 6 12	100.0% 2% 1 Weigh 25.59 4 5.19 5 5.59 2 6.19	Mean Difference t IV, Fixed, 95% CI % 3.81 [2.76, 4.86] % 5.06 [2.80, 7.32] % 4.96 [2.82, 7.10]	-200 -100 0 100 200 Favours [Post-op] Favours [Pre-op] Mean Difference IV, Fixed, 95% Cl
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 S <u>Study or Subgroup</u> Jie Hou 2022 Jing Zhang 2021 Ling Sun 2016 Mengfei Hu 2021 Sheetal Brar 2022	467.21; (Z = 8.06) 0 <u>Mea</u> 46.7 49.1 46.0 47.8 47.4	Chi ² = 3 (P < 0.0) stoper <u>m S</u> (5 2.6 9 3.8 (4 2.3 (6 3.2 (8 2.0)	170 7.98, df 2001) ative <u>D Tot</u> 1 3 7 2 8 5 1 2 4	= 7 (P < Pro al Meai 1 42.9 2 43.1 5 40.9 2 42.3 2 43.7 2 43.7	0.00001 eoperat n SD 4 1.44 9 4.37 8 0.99 9 1.92 2 1.55	170); I ² = 8 ive <u>Total</u> 31 24 6 12 42	100.0% 2% 1 Weigh 25.59 5.59 5.59 2 6.19 2 47.39	Mean Difference t IV, Fixed, 95% CI % 3.81 [2.76, 4.86] % 6.00 [3.66, 8.34] % 5.06 [2.80, 7.32] % 4.96 [2.82, 7.10] % 3.76 [2.99, 4.53]	-200 -100 0 100 200 Favours (Post-op) Favours (Pre-op) Mean Difference IV, Fixed, 95% Cl
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 S <u>Study or Subgroup</u> Jie Hou 2022 Jing Zhang 2021 Ling Sun 2016 Mengfei Hu 2021 Sheetal Brar 2022 Shengtao Liu 2022	467.21; (Z = 8.06) 0 <u>Mea</u> 46.7 49.1 46.0 47.8 47.4 49.6	Stoper m Sign (Sector) 10 Sign (Sector) 11 Sign (Sector) 12 Sign (Sector) 13 Sign (Sector) 14 Sign (Sector) 18 Sign (Sector) 14 Sign (Sector) 15 Sign (Sector) 16 Sign (Sector) 17 Sign (Sector) 18 Sign (Sector) 19 Sign (Sector) 14 Sign (Sector) 15 Sign (Sector) 16 Sign (Sector) 17 Sign (Sector) 18 Sign (Sector) 19 Sign (Sector) 10 Sign (Sector) 11 Sign (Sector) 12 Sign (Sector) 13 Sign (Sector) 14 Sign (Sector)	170 7.98, df 0001) ative <u>D Tot</u> 1 3 7 2 8 5 1 2 4 6	E 7 (P < Pro al Meai 1 42.9 2 43.1 5 40.9 2 42.3 2 43.7 5 44.0	0.00001 eoperat n SD 4 1.44 9 4.37 8 0.99 9 1.92 2 1.55 8 2.35	170); I ² = 8 ive <u>Total</u> 31 24 5 12 42 5	100.0% 2% <u>1 Weigh</u> 2 5.19 5 5.59 2 6.19 2 47.39 5 3.69	Mean Difference t IV, Fixed, 95% CI % 3.81 [2.76, 4.86] % 6.00 [3.66, 8.34] % 5.06 [2.80, 7.32] % 4.96 [2.82, 7.10] % 3.76 [2.99, 4.53] % 5.56 [2.76, 8.36]	-200 -100 0 100 200 Favours (Post-op) Favours (Pre-op) Mean Difference IV, Fixed, 95% Cl
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 S <u>Study or Subgroup</u> Jie Hou 2022 Jing Zhang 2021 Ling Sun 2016 Mengfei Hu 2021 Sheetal Brar 2022 Shengtao Liu 2022 Yuehua Zhou 2015	467.21; (Z = 8.06 (Mea 49.1 46.0 47.8 47.4 47.4 47.4 47.4 47.6 47.8 47.4 47.4 47.6 47.8 47.4 49.6 48.2	Chi ² = 3 (P < 0.0) stoper in Si (5 2.6 9 3.8 (6 3.2 (8 2.0 (8 2.0 (4 2.1 (2 3.9)	170 7.98, df 0001) ative <u>D Tot</u> 1 3 7 2 8 5 1 2 4 6 9 3	Pro al Mean 11 42.9 14 43.1 5 40.9 2 42. 12 43.7 5 44.0 87 43.2	0.00001 eoperati n SD 4 1.44 9 4.37 8 0.99 9 1.92 2 1.55 8 2.35 8 4.82	170); I ² = 8 ive <u>Total</u> 31 24 5 12 42 5 37	Weight 25.59 5.59 5.19 5 5.59 2 6.19 2 47.39 5 3.69 7 6.99	Mean Difference t IV, Fixed, 95% CI % 3.81 [2.76, 4.86] % 6.00 [3.66, 8.34] % 5.06 [2.80, 7.32] % 4.96 [2.82, 7.10] % 3.76 [2.99, 4.53] % 5.56 [2.76, 8.36] % 4.94 [2.92, 6.96]	-200 -100 0 100 200 Favours [Post-op] Favours [Pre-op]
Total (95% CI) Heterogeneity: Tau ² = Test for overall effect: 2 S Study or Subgroup Jie Hou 2022 Jing Zhang 2021 Ling Sun 2016 Mengfei Hu 2021 Sheetal Brar 2022 Shengtao Liu 2022 Yuehua Zhou 2015 Total (95% CI)	467.21; (Z = 8.06 () () () () () () () () () ()	Chi ² = 3 (P < 0.0) stoper <u>m S</u> (5 2.6 9 3.8 9 3.9 9 3.8 9 3.9 9 3.8 9 3.9 9 3.8 9 3.9 9 3.9 9 9 3.9 9 3.9 9 3.9 9 3.9	170 7.98, df 0001) attive <u>D Tot</u> 1 3 7 2 8 5 1 2 4 6 9 3	Pro al Mean 1 42.9 4 43.1 5 40.9 2 42. 2 43.7 5 44.0 37 43.2 66	0.00001 aoperat b b c c c c c c c c	170); I ² = 8 ive <u>Total</u> 31 24 6 12 42 42 6 37 156	Weight 25.59 5.19 5.59 6.19 47.39 7 6.99 6 100.0%	Mean Difference t IV, Fixed, 95% CI % 3.81 [2.76, 4.86] % 5.06 [2.80, 7.32] % 4.96 [2.82, 7.10] % 3.76 [2.99, 4.53] % 5.56 [2.76, 8.36] % 4.94 [2.92, 6.96] % 4.18 [3.65, 4.71]	-200 -100 0 100 200 Favours [Post-op] Favours [Pre-op] Mean Difference IV, Fixed, 95% CI

FIGURE 4

(A) Forest plot showing the weighted mean difference of postoperative CCT and preoperative CCT. (B) Forest plot showing the weighted mean difference of postoperative corneal curvature and preoperative corneal curvature.

	Posto	perati	ve	Preo	perativ	/e		Mean Difference	Mean Difference
study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
liawei Wu 2020	-1.148	0.55	10	-0.25	0.07	10	25.1%	-0.90 [-1.24, -0.55]	_
Sheetal Brar 2022	-0.95	0.28	42	-0.34	0.09	42	37.8%	-0.61 [-0.70, -0.52]	•
Shengtao Liu 2021	-1.25	0.18	14	-0.28	0.11	14	37.1%	-0.97 [-1.08, -0.86]	*
iotal (95% CI)			66			66	100.0%	-0.82 [-1.10, -0.53]	◆
leterogeneity: Tau ² =	: 0.05° Ch	i ² = 25	41 df .	= 2 (P <	0.0000	11) 12 -	a7%		
	0.00, 011	. 20.		- 2 (i -	0.0000	11 <i>1</i> 11 -	02.00		่ว ไม่ ถ่ ไม่ ว่
Fest for overall effect:	Z = 5.58	(P < 0.1	00001)	- 2 (i	0.0000		52.70		-2 -1 0 1 2 Favours (Post-on) Favours (Pre-on)
Test for overall effect:	Z = 5.58	(P < 0.1	00001)	-20	0.0000	,,,, -	52,0		-2 -1 0 1 2 Favours (Post-op) Favours (Pre-op)
Test for overall effect:	Z = 5.58	(P < 0.1	00001)	- 2 (i	0.0000	,,,, -	52,0		-2 -1 0 1 2 Favours (Post-op) Favours (Pre-op)
Test for overall effect:	Z = 5.58 Post	(P < 0.) operat	00001) ive	Pre	operat	ive	52,0	Mean Difference	-2 -1 0 1 2 Favours (Post-op) Favours (Pre-op) Mean Difference
Test for overall effect: Study or Subgroup	Z = 5.58 Post	(P < 0.) operat <u>SD</u>	00001) ive <u>Total</u>	Pre Mean	operat SD	ive	Weight	Mean Difference IV, Fixed, 95% Cl	-2 -1 0 1 2 Favours (Post-op) Favours (Pre-op) Mean Difference IV, Fixed, 95% Cl
Test for overall effect: Study or Subgroup Jiawei Wu 2020	Z = 5.58 Post <u>Mean</u> 0.408	(P < 0.1 operat <u>SD</u> 0.1	ive <u>Total</u>	Pre <u>Mean</u> 0.844	operati <u>SD</u> 0.452	ive Total	Weight 13.3%	Mean Difference <u>IV, Fixed, 95% CI</u> 0 -0.44 [-0.72, -0.15]	-2 -1 0 1 2 Favours (Post-op) Favours (Pre-op) Mean Difference IV, Fixed, 95% Cl
Test for overall effect: <u>Study or Subgroup</u> Jiawei Wu 2020 Sheetal Brar 2022	Z = 5.58 Post <u>Mean</u> 0.408 0.39	(P < 0,1 operat <u>SD</u> 0.1 0.15	ive <u>Total</u> 10 42	Pre <u>Mean</u> 0.844 0.96	operati <u>SD</u> 0.452 0.34	ive Total 10 42	Weight 13.3% 86.7%	Mean Difference IV, Fixed, 95% CI -0.44 [-0.72, -0.15] -0.57 [-0.68, -0.46]	-2 -1 0 1 2 Favours (Post-op) Favours (Pre-op) Mean Difference IV, Fixed, 95% Cl
Test for overall effect: <u>Study or Subgroup</u> Jiawei Wu 2020 Sheetal Brar 2022 Total (95% CI)	Z = 5.58 Post <u>Mean</u> 0.408 0.39	(P < 0.1 operat <u>SD</u> 0.1 0.15	ive <u>Total</u> 10 42	Pre <u>Mean</u> 0.844 0.96	operati <u>SD</u> 0.452 0.34	ive <u>Total</u> 10 42	Weight 13.3% 86.7%	Mean Difference <u>IV, Fixed, 95% CI</u> -0.44 [-0.72, -0.15] -0.57 [-0.68, -0.46] -0.55 [-0.66, -0.45]	-2 -1 0 1 2 Favours (Post-op) Favours (Pre-op) Mean Difference IV, Fixed, 95% Cl
Test for overall effect: <u>Study or Subgroup</u> Jiawei Wu 2020 Sheetal Brar 2022 Total (95% CI) Hotorgoppik: Chi	Z = 5.58 Post <u>Mean</u> 0.408 0.39	(P < 0,1 operat <u>SD</u> 0.1 0.15	ive <u>Total</u> 10 42 52	Pre <u>Mean</u> 0.844 0.96	operati <u>SD</u> 0.452 0.34	ive Total 10 42	<u>Weight</u> 13.3% 86.7% 100.0 %	Mean Difference IV, Fixed, 95% CI -0.44 [-0.72, -0.15] -0.57 [-0.68, -0.46] -0.55 [-0.66, -0.45]	-2 -1 0 1 2 Favours (Post-op) Favours (Pre-op) Mean Difference IV, Fixed, 95% Cl ▲
Test for overall effect: Study or Subgroup Jiawei Wu 2020 Sheetal Brar 2022 Total (95% CI) Heterogeneity: Chi ²	Z = 5.58 Post <u>Mean</u> 0.408 0.39 = 0.73, df	(P < 0.) operat <u>SD</u> 0.1 0.15 = 1 (P	ive <u>Total</u> 10 42 52 = 0.39)	Pre <u>Mean</u> 0.844 0.96	operati <u>SD</u> 0.452 0.34	ive Total 10 42	<u>Weight</u> 13.3% 86.7% 100.0 %	Mean Difference IV, Fixed, 95% CI -0.44 [-0.72, -0.15] -0.57 [-0.68, -0.46] -0.55 [-0.66, -0.45]	-2 -1 0 1 2 Favours [Post-op] Favours [Pre-op] Mean Difference IV, Fixed, 95% Cl -2 -1 0 1 2

(A) Forest plot showing the weighted mean difference of postoperative Q-values and preoperative Q-values. (B) Forest plot showing the weighted mean difference of postoperative HOAs and preoperative HOAs.

autologous and allogeneic transplantation. In our actual clinical work, while paying attention to postoperative visual acuity recovery, we should also pay attention to the long-term safety and changes in corneal morphology after surgery. There is relatively little research on corneal biomechanics and corneal curvature, and the research results have a certain degree of difference. In-depth research can be conducted



in future clinical studies to address this issue, providing more sufficient evidence for the safety and effectiveness of corneal intrastromal lenticule implantation in the treatment of hyperopia.

5 Conclusion

Corneal intrastromal lenticule implantation surgery can effectively improve the refractive state of patients with hyperopia, improve their vision, and reduce the risk of postoperative corneal dilation and keratoconus caused by corneal refractive surgery, achieving the reversibility of corneal refractive surgery.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

Author contributions

YW: Formal analysis, Resources, Writing – original draft. JZ: Formal analysis, Writing – review & editing. ZG: Project administration, Writing – review & editing. XF: Funding acquisition, Visualization, Writing – original draft.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Shenyang Science and Technology Bureau: 22-321-33-87 Hunan Provincial Science and Technology Department: 2020SK50111.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



(A) Funnel plot of postoperative changes in UDVA, (B) funnel plot of postoperative changes in CDVA, (C) funnel plot of postoperative changes in SE, (D) funnel plot of postoperative changes in CCT.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

References

1. Kulp MT, Ciner E, Ying GS, Candy TR, Moore BD, Orel-Bixler D. Vision screening, vision disorders, and impacts of hyperopia in young children: outcomes of the vision in preschoolers (VIP) and vision in preschoolers – hyperopia in preschoolers (VIP-HIP) studies. *Asia-Pacific J Ophthalmol.* (2022) 11:52–8. doi: 10.1097/APO.000000000000483

2. Biscevic A, Pidro A, Pjano MA, Grisevic S, Ziga N, Bohac M. Lasik as a solution for high hypermetropia. *Med Arch.* (2019) 73:191-4. doi: 10.5455/medarh.2019.73.191-194

3. Lee BS. Accuracy and stability of hyperopic treatments. *Curr Opin Ophthalmol.* (2014) 25:281–5. doi: 10.1097/ICU.00000000000066

4. El-Helw MA, Emarah AM. Predictability and stability of refraction with increasing optical zone diameter in hyperopic LASIK. *Clin Ophthal*. (2010) 4:455–8. doi: 10.2147/ OPTH.S11007

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

5. Pedrotti E, Cozzini T, Fasolo A, Bonacci E, Bonetto J, Merz T, et al. Small-incision lenticule addition in ex vivo model of ectatic human corneas. *Int Ophthalmol.* (2019) 39:2575–81. doi: 10.1007/s10792-019-01106-8

6. Fasolo A, Galzignato A, Pedrotti E, Chierego C, Cozzini T, Bonacci E, et al. Femtosecond laser-assisted implantation of corneal stroma lenticule for keratoconus. *Int Ophthalmol.* (2021) 41:1949–57. doi: 10.1007/s10792-021-01739-8

7. Jiang Y, Li Y, Liu XW, Xu J. A novel tectonic keratoplasty with femtosecond laser intrastromal lenticule for corneal ulcer and perforation. *Chin Med J.* (2016) 129:1817–21. doi: 10.4103/0366-6999.186639

8. Pant OP, Hao JL, Zhou DD, Lu CW. Tectonic keratoplasty using femtosecond laser lenticule in pediatric patients with corneal perforation secondary to blepharokeratoconjunctivitis: a case report and literature review. *J Int Med Res.* (2019) 47:2312–20. doi: 10.1177/0300060519841163 9. Zhou Y, Zhang J, Zheng Y, Liu Q, Wei W, Wang N. The early clinical efficacy of allogeneic corneal lens inlays in correction of hyperopia. *Zhonghua Yan Ke Za Zhi [Chin J Ophthalmol]*. (2015) 51:683–8.

10. Zhang J, Zhou Y. Small incision lenticule extraction (SMILE) combined with allogeneic intrastromal lenticule inlay for hyperopia with astigmatism. *PLoS One*. (2021) 16:7667. doi: 10.1371/journal.pone.0257667

11. Santra M, Liu YC, Jhanji V, Yam GH. Human SMILE-derived stromal Lenticule scaffold for regenerative therapy: review and perspectives. *Int J Mol Sci.* (2022) 23:967. doi: 10.3390/ijms23147967

12. Yin H, Qiu P, Wu F, Zhang W, Teng W, Qin Z, et al. Construction of a corneal stromal equivalent with SMILE-derived lenticules and fibrin glue. *Sci Rep.* (2016) 6:33848. doi: 10.1038/srep33848

13. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* (2009) 6:e1000097. doi: 10.1371/journal.pmed.1000097

14. Santos WMD, Secoli SR, Püschel VAA. The Joanna Briggs institute approach for systematic reviews. *Rev Lat Am Enfermagem.* (2018) 26:e3074. doi: 10.1590/1518-8345.2885.3074

15. Magesh S, John D, Li WT, Li Y, Mattingly-app A, Jain S, et al. Disparities in COVID-19 outcomes by race, ethnicity, and socioeconomic status: a systematic-review and meta-analysis. *JAMA Netw Open*. (2021) 4:e2134147. doi: 10.1001/jamanetworkopen.2021.34147

16. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. *ANZ J Surg.* (2003) 73:712–6. doi: 10.1046/j.1445-2197.2003.02748.x

17. Hou K, Yu Z, Jia Y, Fang H, Shao S, Huang L, et al. Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: a single-arm meta-analysis. *Crit Rev Oncol Hematol.* (2020) 152:103010. doi: 10.1016/j.critrevonc.2020.103010

18. West CP, Dyrbye LN, Erwin PJ, Shanafelt TD. Interventions to prevent and reduce physician burnout: a systematic review and meta-analysis. *Lancet*. (2016) 388:2272–81. doi: 10.1016/S0140-6736(16)31279-X

19. Chia MA, Taylor JR, Stuart KV, Khawaja AP, Foster PJ, Keane PA, et al. Prevalence of diabetic retinopathy in indigenous and non-indigenous Australians: a systematic review and meta-analysis. *Ophthalmology.* (2023) 130:56–67. doi: 10.1016/j. ophtha.2022.07.024

20. Hou J, Wang Y, Zhang J, Lei Y, Ma Z, Zhang Y, et al. Corneal densitometry after allogeneic small-incision intrastromal lenticule implantation for hyperopia correction. *BMC Ophthalmol.* (2022) 22:286. doi: 10.1186/s12886-022-02454-3

21. Wu J, Xiong L, Wang Z, Reinstein DZ, Vida RS, Archer TJ. Correction of moderate to high hyperopia with implantation of an allogeneic refractive lenticule. *J Refract Surg.* (2020) 36:772–9. doi: 10.3928/1081597X-20200826-01

22. Brar S, Ganesh S, Sriganesh SS, Bhavsar H. Femtosecond intrastromal Lenticule implantation (FILI) for management of moderate to high hyperopia: 5-year outcomes. *J Refract Surg.* (2022) 38:348–54. doi: 10.3928/1081597X-20220503-01

23. Li M, Li M, Sun L, Ni K, Zhou X. Predictive formula for refraction of autologous lenticule implantation for hyperopia correction. *J Refract Surg.* (2017) 33:827–33. doi: 10.3928/1081597X-20171016-01

24. Sun L, Yao P, Li M, Shen Y, Zhao J, Zhou X. The safety and predictability of implanting autologous lenticule obtained by SMILE for hyperopia. *J Refract Surg.* (2015) 31:374–9. doi: 10.3928/1081597X-20150521-03

25. Liu S, Zhang X, Zhou X. Toric Lenticule implantation for correction of hyperopia and astigmatism following small incision Lenticule intrastromal Keratoplasty with the triple marking method. *J Refract Surg.* (2022) 38:82–8. doi: 10.3928/1081597X-20211117-01

26. Liu S, Wei R, Choi J, Li M, Zhou X. Visual outcomes after implantation of allogenic Lenticule in a 100-mu m pocket for moderate to high hyperopia: 2-year results. *J Refract Surg.* (2021) 37:734–40. doi: 10.3928/1081597X-20210730-02

27. Hu M, Li S, Xing X. The attempt for correcting the hyperopia and anisometropia with the femtosecond laser corneal stromal lenticule extraction and autologous transplantation. *Zhonghua Yan Wai Shang Za Zhi.* (2021) 43:e9. doi: 10.3760/cma.j. cn116022-20210608-00179

28. Llovet F, Galal A, Benitez-del-Castillo JM, Ortega J, Martin C, Baviera J. One-year results of excimer laser in situ keratomileusis for hyperopia. *J Cataract Refract Surg.* (2009) 35:1156–65. doi: 10.1016/j.jcrs.2009.03.014

29. Dave R, O'Brart DPS, Wagh VK, Lim WS, Patel P, Lee J, et al. Sixteen-year followup of hyperopic laser in situ keratomileusis. *J Cataract Refract Surg.* (2016) 42:717–24. doi: 10.1016/j.jcrs.2016.03.028

30. Nassiri N, Sheibani K, Azimi A, Khosravi FM, Heravian J, Yekta A, et al. Refractive outcomes, contrast sensitivity, HOAs, and patient satisfaction in moderate myopia: Wavefront-optimized versus tissue-saving PRK. *J Refract Surg.* (2015) 31:683–90. doi: 10.3928/1081597X-20150831-01

31. Miraftab M, Hashemi H, Aghamirsalim M, Fayyaz S, Asgari S. Matched comparison of corneal higher order aberrations induced by SMILE to femtosecond assisted LASIK and to PRK in correcting moderate and high myopia: 3.00mm vs. 6.00mm. *BMC Ophthalmol.* (2021) 21:e3. doi: 10.1186/s12886-021-01987-3

32. Zhou X, Qin B, Han T, Shang J, Chen Z, Zhao J, et al. Long-term observation of higher-order aberrations and microdistortions in Bowman's layer after small incision Lenticule extraction for the correcting myopia with spherical equivalent higher than –9.0 diopters. *Front Med.* (2022) 9:814810. doi: 10.3389/fmed.2022.814810

33. Mostafa MM, Abdelmotaal H, Abdelazeem K, Goda I, Abdel-Radi M. Q-value customized versus wavefront-optimized ablation in femtosecond laser-assisted LASIK for myopia and myopic astigmatism: a prospective contralateral comparative study. *Eye Vision*. (2022) 9:43. doi: 10.1186/s40662-022-00312-3

34. Iqbal M, Elmassry A, Mounir A, Ibrahim O, Soliman A. A novel Q-value-based nomogram for single intracorneal ring segment implantation versus standard manufacturer's nomogram combined with accelerated cross-linking for treatment of keratoconus: a randomized controlled trial. *Acta Ophthalmol.* (2021) 99:e501–11. doi: 10.1111/aos.14611

35. Zhang J, Zheng L, Zhao X, Sun Y, Feng W, Yuan M. Corneal aberrations after small-incision lenticule extraction versus Q value-guided laser-assisted in situ keratomileusis. *Medicine*. (2019) 98:e14210. doi: 10.1097/MD.000000000014210

36. Bohac M, Koncarevic M, Pasalic A, Biscevic A, Merlak M, Gabric N, et al. Incidence and clinical characteristics of post LASIK ectasia: a review of over 30,000 LASIK cases. *Semin Ophthalmol.* (2018) 33:869–77. doi: 10.1080/08820538.2018.1539183

37. Lagali N. Corneal stromal regeneration: current status and future therapeutic potential. *Curr Eye Res.* (2020) 45:278–90. doi: 10.1080/02713683.2019.1663874

38. Mohan RR, Kempuraj D, D'Souza S, Ghosh A. Corneal stromal repair and regeneration. *Prog Retin Eye Res.* (2022) 91:101090. doi: 10.1016/j.preteyeres.2022.101090

39. Liu R, Zhao J, Xu Y, Li M, Niu L, Liu H, et al. Femtosecond laser-assisted corneal small incision allogenic intrastromal lenticule implantation in monkeys: a pilot study. *Invest Ophthalmol Vis Sci.* (2015) 56:3715–20. doi: 10.1167/iovs.14-15296

40. Mohamed-Noriega K, Toh KP, Poh R, Balehosur D, Riau A, Htoon HM. Cornea lenticule viability and structural integrity after refractive lenticule extraction (ReLEx) and cryopreservation. *Mol Vis.* (2011) 17:3437–49.

41. Liu YC, Williams GP, George BL, Soh YQ, Seah XY, Peh GSL, et al. Corneal lenticule storage before reimplantation. *Mol Vis.* (2017) 23:753–64.

42. Xia F, Zhao J, Fu D, Qin B, Chen Z, Zhao Y, et al. Comparison of the effects of temperature and dehydration mode on glycerin-based approaches to SMILE-derived Lenticule preservation. *Cornea.* (2022) 41:470–7. doi: 10.1097/ICO.00000000002846